Loading…

NovoCure Ltd.NVCRCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of Tumor Treating Fields devices, a wearable cancer therapy using electric fields to disrupt tumor cell division.

Momentum laggard 10
Mkt cap
$1.25B
US dollars, full cap
Free float
90%
of shares outstanding
$/day
$24.8M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-100.4 pp
WACC 9.8%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$10.73
1D-3.7%
1W-10.5%
1M-31.7%
3M-39.6%
6M-39.5%
YTD-17.0%
1Y-4.8%
ATR %7.1%
Beta1.52
52w lowhigh50.0% off high

What NovoCure does

Maker of Tumor Treating Fields devices, a wearable cancer therapy using electric fields to disrupt tumor cell division.

Bills insurers for each month a patient stays on therapy, with the device and support services included, so revenue follows the number of active patients and how long they stay on treatment rather than one-off device sales. Glioblastoma, an aggressive brain cancer, is the long-standing franchise; the 2024 US approval of the lung-cancer version opened a second.

Products and services

  • Optune (glioblastoma TTFields)
  • Optune Lua (lung cancer TTFields)
  • Pipeline TTFields for other solid tumors

Customers

  • Oncologists
  • Cancer patients (glioblastoma, mesothelioma, NSCLC

Where it sits in the supply chain

  • Medical devices
  • Oncology bioelectric therapy
  • Wearable electric-field cancer…

What could go right

  • Label expansion into new cancer types
  • International reimbursement expansion

What could go wrong

  • Patient compliance/wearability burden
  • Clinical trial outcome risk in new indications

Moat: narrow (IP / patents, regulatory licence). Patented TTFields technology is a unique treatment modality with no direct device competitor.

Headquarters: Root, Switzerland · Founded: 2000 · Employees: 1,605

Named competitors

NovoCure at a glance

Size NovoCure (NVCR) is a United States Health Care company (Medical Specialties) with a market value of $1.25B, the 2090th largest of 3,085 United States companies the cockpit tracks. Shares closed at $10.73 on 18 Nov 2026.

Performance Over six months the shares fell 39.5%, against -14.3% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd lowest of 20 in its peer set.

Growth Revenue grew 12.9% over the last twelve months (peer median +10.8%); the operating margin is -17.2% (peer median 11.6%).

Valuation It trades at 1.4× enterprise value to sales against a peer median of 3.8× (2nd cheapest of 20).

Capital Return on invested capital runs 100.4 points below its cost of capital (9.8% WACC).

Short interest Short interest is 11.1% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 86NVCR 60
Six months, rebased to 100: NovoCure against the median of its 20 peers (local-currency closes).

NovoCure financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$725M$655M$605M$509M$538M
Revenue growth—+8%+19%-5%—
Gross profit$559M$490M$469M$382M$424M
EBITDA-$107M-$137M-$156M-$215M-$78.3M
Net income-$122M-$136M-$169M-$207M-$92.5M
Free cash flow-$24.6M-$75.7M-$69.2M-$100M$9.43M
Capital expenditure$23.9M$26.6M$42.9M$27.1M$21.4M
Total debt$232M$248M$683M$604M$590M

Quarterly statements and history in the cockpit →

NovoCure competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%-40%-20%0%+20%688289STAA6880502675300633688758688198TNDM688161300406DRTSCNMDATECPRCT300298300049214150NVCR6-month return →1-month return →
Up and to the right = strong over both horizons. NovoCure is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%5×10×15×688289STAA6880502675300633688758688198TNDM300595688161300406CNMDPRCT300049214150NVCRRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. NovoCure is the large dot.

NovoCure competitors and peer comparison

Head to head with its named competitors (NVCR vs BMY vs MRK vs AZN.L)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
NovoCure NVCR$1.25B-40%+13%-17%1.4×n/a
Bristol Myers Squibb BMY$122B+3%+4%33%3.1×-13.1%
Merck & MRK$340B+23%+5%18%5.7×8.3%
AstraZeneca AZN.L$278B-2%+5%23%5.0×14.4%

How NovoCure compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

NovoCure against its 20 peers (data as of 18 Nov 2026)
MeasureNVCRPeer medianRank in peer set
1-month return-31.7%-1.9%2nd lowest of 21
6-month return-39.5%-14.3%3rd lowest of 20
Distance from 52-week high-50.0%-38.5%6th lowest of 21
Revenue growth (TTM)+12.9%+10.8%9th highest of 19
Operating margin-17.2%11.6%2nd lowest of 20
EV / Sales1.4×3.8×2nd cheapest of 20
ROIC minus cost of capital-100.4 pp+0.2 pplowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
NovoCure NVCRUnited States$1.25B-40%+13%-17%1.4×n/an/a
Sansure Biotech 688289.SSChina$1.24B-17%-1%1%3.8×n/an/a
STAAR Surgical STAAUnited States$1.27B-23%+42%7%3.4×35.1%+7.9%
Eyebright Medical Technology (Beijing) 688050.SSChina$1.21B-16%+21%16%5.0×10.3%+40.3%
Shenzhen Edge Medical 2675.HKHong Kong$1.21B-51%+132%2%10.6×n/an/a
Sonoscape Medical 300633.SZChina$1.31B-10%+18%4%3.3×n/an/a
Suzhou Sepax Technologies 688758.SSChina$1.31B+8%+28%40%15.4×22.8%+23.6%
Beijing Balance Medical Technology 688198.SSChina$1.31B-32%+10%28%13.4×20.7%+27.6%
Tandem Diabetes Care TNDMUnited States$1.19B+13%+7%-2%1.4×n/an/a
Ovctek China 300595.SZChina$1.33B-25%0%28%3.8×8.3%+16.5%
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%4.7×11.3%-3.5%
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%5.8×1.7%+9.9%
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
CONMED CNMDUnited States$1.43B+30%+2%2%1.6×31.6%+9.8%
Alphatec ATECUnited States$1.10B-14%+15%-3%1.9×n/an/a
PROCEPT BioRobotics PRCTUnited States$1.45B-10%+17%-34%3.7×n/an/a
Freenome FRNMUnited States$1.08Bn/an/a36%4.7×n/an/a
Sinocare 300298.SZChina$1.45B+4%+7%6%2.0×9.5%+18.3%
Inner Mongolia Furui Medical Science 300049.SZChina$1.45B-31%+11%25%6.0×2.9%+14.6%
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%4.0×-9.2%+34.5%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%1.7×5.9%+3.6%

Questions

Who are NovoCure's main competitors?
Named competitors: Bristol Myers Squibb (BMY), Merck & Co (MRK), AstraZeneca (AZN.L). The cockpit's measured peer set (industry) also includes Sansure Biotech (688289.SS), STAAR Surgical (STAA), Eyebright Medical Technology (Beijing) (688050.SS), Shenzhen Edge Medical (2675.HK), Sonoscape Medical (300633.SZ), Suzhou Sepax Technologies (688758.SS).
Is NovoCure expensive compared with its peers?
On ev / sales it trades at 1.4× against a peer median of 3.8×, 2nd cheapest of 20 in its peer set.
How has NovoCure stock performed?
Over six months to 18 Nov 2026 the shares returned -39.5% against -14.3% for the median peer; over one year -4.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.